We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS) (C2 -CORVUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00921752
Recruitment Status : Completed
First Posted : June 16, 2009
Last Update Posted : December 4, 2009
Sponsor:
Information provided by:

June 12, 2009
June 16, 2009
December 4, 2009
May 2009
Not Provided
  • Percent rate of patients achieving target LDL cholesterol goals [ Time Frame: On each of the 3 visits performed during the study ]
  • Percent rate of patients achieving 50% or more reduction in LDL-cholesterol [ Time Frame: On each of the 3 visits performed during the study ]
Same as current
Complete list of historical versions of study NCT00921752 on ClinicalTrials.gov Archive Site
  • Percent rate of patients achieving target secondary (total Ch, triglycerides, HDL Ch) goals [ Time Frame: On each of the 3 visits performed during the study ]
  • Percent rate of compliance among patients in the study [ Time Frame: On each of the 3 visits performed during the study ]
Same as current
Not Provided
Not Provided
 
C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)
C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)
To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Ambulatory clinics
Cardiovascular Risk
Not Provided
Patients at high cardiovascular risk

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1500
November 2009
Not Provided

Inclusion Criteria:

  • Patients at high cardiovascular risk according to Framingham or SCORE rates

Exclusion Criteria:

  • Not eligible for lipid or statin therapy
  • Intolerance to therapy
  • Patients at low or intermediate CV risk
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Hungary
 
 
NCT00921752
NIS-CHU-DUM-2009/1
No
Not Provided
Not Provided
MC MD, AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Mark Laszlo, MD, PHD County Hospital Bekes, Gyula
Study Director: Csaba Csongvai, MD AstraZeneca Hungary
Study Chair: Eva Gulyas AstraZeneca Hungary
AstraZeneca
December 2009